Peter Hein is an MD/PhD with extensive background in academic basic research as well as in the pharmaceutical industry. In his academic research he focussed on G protein-coupled receptors, including developing assays to monitor signal transduction in real time. Working at Grünenthal, Aachen, Germany, he has led translational and early clinical project teams to help bring new drug candidates to humans, and supported novel networked R&D models. Peter currently works as a Medical Director, Experimental Medicine, at Bayer, Germany, and is a co-founder of the biotech consultancy TherapeutAix.
Peter Hein is an MD/PhD with extensive background in academic basic research as well as in the pharmaceutical industry. In his academic research he focussed on G protein-coupled receptors, including developing assays to monitor signal transduction in real time. Working at Grünenthal, Aachen, Germany, he has led translational and early clinical project teams to help bring new drug candidates to humans, and supported novel networked R&D models. Peter currently works as a Medical Director, Experimental Medicine, at Bayer, Germany, and is a co-founder of the biotech consultancy TherapeutAix.